Tenet Healthcare Corp.
Congress has disclosed 9 buys and 9 sells of THC (Tenet Healthcare Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
how it's calculated
how it's calculated
how it's calculated
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
18 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jonathan Jackson | House | SELL ◆ insider convergence · moderate | Spouse · Morgan Stanley - Rollover IRA | 2026-04-15 | 23 days | -1.6% | $1K–$15K 0.3% of NW |
12.9 | ↗ filing |
| Jonathan Jackson | House | SELL ◆ insider convergence · moderate | Spouse · Morgan Stanley - Rollover IRA | 2026-02-11 | 20 days | +7.3% | $1K–$15K 0.3% of NW |
17.6 | ↗ filing |
| Jonathan Jackson | House | BUY ◆ insider divergence · moderate | Joint · Morgan Stanley Trust Account | 2025-12-10 | 26 days | +4.8% | $15K–$50K 1.1% of NW |
53.6 | ↗ filing |
| Jonathan Jackson | House | BUY ◆ insider divergence · moderate | Spouse · Morgan Stanley - Rollover IRA | 2025-09-03 | 33 days | +6.9% | $1K–$15K 0.3% of NW |
64.6 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider convergence · moderate | Spouse · Charles Schwab Brokerage Account 924 | 2025-08-04 | 9 days | +6.7% | $1K–$15K 0.1% of NW |
84.7 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider divergence · moderate | Spouse · Charles Schwab Brokerage Account 924 | 2025-06-11 | 63 days | +6.5% | $1K–$15K 0.1% of NW |
97.4 | ↗ filing |
| John James | House | SELL ◆ insider convergence · moderate | Self · John A. James Children’s Trust | 2024-09-04 | 1 days | -0.1% | $1K–$15K <0.1% of NW |
84.6 | ↗ filing |
| John James | House | BUY ◆ insider divergence | Self · John A. James Children’s Trust | 2023-11-10 | 277 days | — | $1K–$15K <0.1% of NW |
98.8 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2017-05-04 | 28 days | — | $1K–$15K | 2.6 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2017-05-03 | 29 days | — | $1K–$15K | 4.5 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2017-03-02 | 30 days | — | $1K–$15K | 5.5 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2017-03-01 | 31 days | — | $1K–$15K | 6.8 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2017-02-28 | 1 days | — | $1K–$15K | 8.6 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2016-10-21 | 11 days | — | $1K–$15K | 10.6 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2016-10-20 | 12 days | — | $1K–$15K | 15.7 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2015-07-07 | 25 days | — | $1K–$15K | 22.3 | ↗ filing |
| Thomas MacArthur | House | BUY | Joint | 2015-07-02 | 30 days | — | $1K–$15K | 40.4 | ↗ filing |
| Thomas MacArthur | House | SELL | Joint | 2015-03-26 | 6 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in THC — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
Of the congressional trades in THC, 4 coincided with corporate insiders moving the same way within 60 days, and 4 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-09-14 | KERREY J ROBERT | Director | SELL | $1.4M | ↗ EDGAR |
| 2026-09-14 | KERREY J ROBERT | Director | SELL | $1.1M | ↗ EDGAR |
| 2026-09-14 | KERREY J ROBERT | Director | SELL | $662K | ↗ EDGAR |
| 2026-09-10 | MARK RICHARD J | Director | SELL | $2.6M | ↗ EDGAR |
| 2026-09-02 | West Nadja | Director | SELL | $298K | ↗ EDGAR |
| 2026-08-31 | Foo Lisa Y | C-suite | SELL | $6.4M | ↗ EDGAR |
| 2026-08-25 | Sutaria Saumya | C-suite | SELL | $4.7M | ↗ EDGAR |
| 2026-08-25 | Sutaria Saumya | C-suite | SELL | $6.8M | ↗ EDGAR |
| 2026-08-25 | Sutaria Saumya | C-suite | SELL | $2.2M | ↗ EDGAR |
| 2026-08-24 | Sutaria Saumya | C-suite | SELL | $3.7M | ↗ EDGAR |
| 2026-08-24 | Sutaria Saumya | C-suite | SELL | $10.2M | ↗ EDGAR |
| 2026-08-24 | HANEY CECIL D | Director | SELL | $361K | ↗ EDGAR |
| 2026-08-07 | Romo Tammy | Director | SELL | $652K | ↗ EDGAR |
| 2026-08-06 | Romo Tammy | Director | SELL | $1.3M | ↗ EDGAR |
| 2026-08-05 | Blunt Roy | Director | SELL | $158K | ↗ EDGAR |
| 2026-07-29 | Foo Lisa Y | C-suite | SELL | $2.6M | ↗ EDGAR |
| 2026-07-27 | BIERMAN JAMES L | Director | SELL | $1.2M | ↗ EDGAR |
| 2026-07-27 | Arbour Paola M | C-suite | SELL | $2.7M | ↗ EDGAR |
| 2026-07-27 | Lynch Christopher S. | Director | SELL | $934K | ↗ EDGAR |
| 2026-05-28 | KERREY J ROBERT | Director | SELL | $341K | ↗ EDGAR |
| 2026-05-28 | KERREY J ROBERT | Director | SELL | $294K | ↗ EDGAR |
| 2026-05-28 | KERREY J ROBERT | Director | SELL | $125K | ↗ EDGAR |
| 2026-05-28 | KERREY J ROBERT | Director | SELL | $160K | ↗ EDGAR |
| 2026-05-28 | KERREY J ROBERT | Director | SELL | $64K | ↗ EDGAR |
| 2026-05-27 | West Nadja | Director | SELL | $532K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| ◆ insider | 2026-09-14 | KERREY J ROBERT Director | SELL | $1.4M |
| ◆ insider | 2026-09-14 | KERREY J ROBERT Director | SELL | $1.1M |
| ◆ insider | 2026-09-14 | KERREY J ROBERT Director | SELL | $662K |
| ◆ insider | 2026-09-10 | MARK RICHARD J Director | SELL | $2.6M |
| ◆ insider | 2026-09-02 | West Nadja Director | SELL | $298K |
| ◆ insider | 2026-08-31 | Foo Lisa Y C-suite | SELL | $6.4M |
| ◆ insider | 2026-08-25 | Sutaria Saumya C-suite | SELL | $4.7M |
| ◆ insider | 2026-08-25 | Sutaria Saumya C-suite | SELL | $6.8M |
| ◆ insider | 2026-08-25 | Sutaria Saumya C-suite | SELL | $2.2M |
| ◆ insider | 2026-08-24 | Sutaria Saumya C-suite | SELL | $3.7M |
| ◆ insider | 2026-08-24 | Sutaria Saumya C-suite | SELL | $10.2M |
| ◆ insider | 2026-08-24 | HANEY CECIL D Director | SELL | $361K |
| ◆ insider | 2026-08-07 | Romo Tammy Director | SELL | $652K |
| ◆ insider | 2026-08-06 | Romo Tammy Director | SELL | $1.3M |
| ◆ insider | 2026-08-05 | Blunt Roy Director | SELL | $158K |
| ◆ insider | 2026-07-29 | Foo Lisa Y C-suite | SELL | $2.6M |
| ◆ insider | 2026-07-27 | BIERMAN JAMES L Director | SELL | $1.2M |
| ◆ insider | 2026-07-27 | Arbour Paola M C-suite | SELL | $2.7M |
| ◆ insider | 2026-07-27 | Lynch Christopher S. Director | SELL | $934K |
| ◆ insider | 2026-05-28 | KERREY J ROBERT Director | SELL | $341K |
| ◆ insider | 2026-05-28 | KERREY J ROBERT Director | SELL | $294K |
| ◆ insider | 2026-05-28 | KERREY J ROBERT Director | SELL | $125K |
| ◆ insider | 2026-05-28 | KERREY J ROBERT Director | SELL | $160K |
| ◆ insider | 2026-05-28 | KERREY J ROBERT Director | SELL | $64K |
FAQ Common questions
How much has Congress traded THC?
9 disclosed buys and 9 sells of THC (Tenet Healthcare Corp.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade THC?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.